Covid-19
Video: Coronavirus Update with Carlos del Rio and Preeti Malani
19 Mar, 2021 | 08:24h | UTCCoronavirus Update With Carlos del Rio and Preeti Malani – JAMA
Perspective | Five reasons why COVID herd immunity is probably impossible
19 Mar, 2021 | 08:19h | UTCFive reasons why COVID herd immunity is probably impossible – Nature
Opinion | “’It’s a very special picture.’ Why vaccine safety experts put the brakes on AstraZeneca’s COVID-19 vaccine”
18 Mar, 2021 | 09:14h | UTC‘It’s a very special picture.’ Why vaccine safety experts put the brakes on AstraZeneca’s COVID-19 vaccine – Science (a few articles per month are free)
Related: Update on the safety of COVID-19 Vaccine AstraZeneca (statement and commentaries)
WHO Statement | The benefits of the AstraZeneca vaccine outweigh its risks – vaccinations should continue
18 Mar, 2021 | 09:17h | UTCWHO statement on AstraZeneca COVID-19 vaccine safety signals – World Health Organization
Related: Update on the safety of COVID-19 Vaccine AstraZeneca (statement and commentaries)
Commentary on Twitter (thread – click for more)
At this time, WHO considers that the benefits of the AstraZeneca vaccine outweigh its risks and recommends that vaccinations continue.
Full statement on AstraZeneca #COVID19 vaccine safety signals:
? https://t.co/9J6MtxXWK8 pic.twitter.com/fWGzqbjMuE— World Health Organization (WHO) (@WHO) March 17, 2021
Opinion | “The zero-risk mentality stifling Europe is now killing its people”
18 Mar, 2021 | 09:11h | UTCThe zero-risk mentality stifling Europe is now killing its people – The Sidney Morning Herald
Related: Update on the safety of COVID-19 Vaccine AstraZeneca (statement and commentaries)
Systematic Review: Thoracic imaging tests for the diagnosis of COVID‐19
18 Mar, 2021 | 09:05h | UTCThoracic imaging tests for the diagnosis of COVID‐19 – Cochrane Library
Opinion | “Oxford-AstraZeneca Vaccine Safety: Reports of blood clots after receiving the AstraZeneca COVID-19 vaccine are very likely just background events.”
18 Mar, 2021 | 09:09h | UTCRelated: Update on the safety of COVID-19 Vaccine AstraZeneca (statement and commentaries) AND What is Going on With the AstraZeneca/Oxford Vaccine? – Science Translational Medicine
Just How Do Deaths Due to COVID-19 Stack Up?
18 Mar, 2021 | 09:03h | UTCJust How Do Deaths Due to COVID-19 Stack Up? – Think Global Health
Commentary on Twitter (thread – click for more)
The Americas and Europe accounted for 80% of COVID-19 deaths globally, even though they represent only a quarter of the world's population. @ThinkGlobalHlth launches a tracker of COVID as a cause of death globally and the factors driving those trends 1/https://t.co/t6xp2yAWA4 pic.twitter.com/SJ9DRdlu1e
— Tom Bollyky (@TomBollyky) March 17, 2021
Long Covid | Four-month clinical status of a cohort of patients after hospitalization for COVID-19
18 Mar, 2021 | 09:00h | UTCFour-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19 – JAMA
Editorial: Outcomes for Patients Following Hospitalization for COVID-19
Why Opening Windows Is a Key to Reopening Schools
18 Mar, 2021 | 09:02h | UTCWhy Opening Windows Is a Key to Reopening Schools – The New York Times (free registration may be required)
Commentary on Twitter
Stunning #AR imagery to underscore the importance of ventilation and window opening for countering covid in schools (and all places) https://t.co/uWhJie1Sku by @NickBartzokas and colleagues w/ @j_g_allen ✓ out the digital version pic.twitter.com/gXxjH1VbTo
— Eric Topol (@EricTopol) March 17, 2021
COVID-19 vaccines vs. variants—determining how much immunity is enough
18 Mar, 2021 | 08:58h | UTCCOVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough – JAMA
Population Study: Past Covid-19 confers 80.5% protection against reinfection, which decreases to 47.1% in those aged 65 years and older
18 Mar, 2021 | 09:06h | UTCCommentaries: Risk of SARS-CoV-2 reinfection after natural infection – The Lancet AND COVID-19 Reinfection: More Common Than We Think? – MedPage Today (free registration required)
Commentary on Twitter
NEW—Most people who have had original #COVID19 strain are protected from catching it again for at least 6 months—but those ≥65 years are more prone to reinfection, suggests first large-scale study of its kind. Read https://t.co/250Yv0a9BZ pic.twitter.com/BTjhcMzXwT
— The Lancet (@TheLancet) March 17, 2021
[Preprint] Delaying second vaccine dose leaves cancer patients vulnerable to virus
17 Mar, 2021 | 02:58h | UTCNews release: Delaying second vaccine dose leaves cancer patients vulnerable to virus – King’s College London
Commentaries: Expert reaction to preprint looking at antibody immune response following one dose of Pfizer COVID-19 vaccine in cancer patients – Science Media Centre AND Cancer patients ‘lack same protection’ after first jab – BBC
WHO points to wildlife farms in southern China as likely source of pandemic
17 Mar, 2021 | 03:02h | UTCWHO Points To Wildlife Farms In Southern China As Likely Source Of Pandemic – wbur
WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic
17 Mar, 2021 | 03:04h | UTC
Immunogenicity of a single dose of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients
17 Mar, 2021 | 02:55h | UTC
RCT: Oxford/AstraZeneca vaccine does not protect against mild-to-moderate Covid-19 due to the B.1.351 variant
17 Mar, 2021 | 03:01h | UTCCommentaries: AstraZeneca vaccine doesn’t prevent B1351 COVID in early trial – CIDRAP AND Oxford/AstraZeneca Fails to Prevent Mild to Moderate Covid-19 From B.1.351 (“South Africa”) Variant – Brief19
FDA: Why you should not use Ivermectin to treat or prevent COVID-19
17 Mar, 2021 | 02:51h | UTCWhy You Should Not Use Ivermectin to Treat or Prevent COVID-19 – U.S. Food & Drug Administration
Commentary: FDA Rejects Ivermectin, Despite Growing Interest In Some Corners Of The Internet – Brief19
Related: RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19
COVID‐19 and its cardiovascular effects: a systematic review of prevalence studies
17 Mar, 2021 | 02:52h | UTC
Commentary on Twitter
How common are pre‐existing heart & blood vessel problems in #COVID19? What are most common complications affecting heart & blood vessels in #COVID19? @CochraneHeart review of prevalence studies: https://t.co/rDqz2GyrpH
— The Cochrane Library (@CochraneLibrary) March 12, 2021
Imaging review of peripheral nerve injuries in patients with COVID-19
17 Mar, 2021 | 02:48h | UTCImaging Review of Peripheral Nerve Injuries in Patients with COVID-19 – Radiology
‘Then the world caved in’: 11 experts describe the day they realized Covid-19 was here to stay
17 Mar, 2021 | 02:49h | UTC
COVID antibody treatments show promise for preventing severe disease
17 Mar, 2021 | 02:46h | UTCCOVID antibody treatments show promise for preventing severe disease – Nature
Update on the safety of COVID-19 Vaccine AstraZeneca
16 Mar, 2021 | 02:35h | UTCUpdate on the safety of COVID-19 Vaccine AstraZeneca
Related: Countries should continue AstraZeneca rollout: WHO – MedicalXpress AND Expert reaction to news that Germany has halted vaccinations with the Oxford-AstraZeneca COVID-19 vaccine – Science Media Centre AND AstraZeneca finds no evidence of increased blood clot risk from vaccine – Reuters AND Data suggest no increased risk of blood clots from the AstraZeneca vaccine. Australia shouldn’t pause its rollout – The Conversation
Commentary on Twitter
As of March 8th, Around 17 million people in the EU & UK received the vaccine , there have been 15 events of DVT & 22 events of pulmonary embolism reported among those given the vaccine,This is much lower than would be expected to occur naturally in a general population
Please RT https://t.co/tnn4brxwpp— Antibiotic Steward? Bassam Ghanem (@ABsteward) March 14, 2021
B.1.1.7 variant linked to 55% higher mortality compared to other strains of SARS-CoV-2
16 Mar, 2021 | 02:32h | UTCOriginal study: Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 – Nature
Related: Death rate 64% higher with B117 COVID variant, study finds (study and commentary)
Commentary on Twitter (thread – Click for more)
https://mobile.twitter.com/_nickdavies/status/1371441682089132032
Antibody response after SARS-CoV-2 infection and implications for immunity: A rapid living review
16 Mar, 2021 | 02:30h | UTC